152 related articles for article (PubMed ID: 35321517)
1. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
4. Disitamab Vedotin: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
[No Abstract] [Full Text] [Related]
7. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
[TBL] [Abstract][Full Text] [Related]
9. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
[TBL] [Abstract][Full Text] [Related]
10. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report.
Zhou JH; Yi QJ; Li MY; Xu Y; Dong Q; Wang CY; Liu HY
World J Clin Cases; 2024 Feb; 12(4):820-827. PubMed ID: 38322681
[TBL] [Abstract][Full Text] [Related]
11. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
Qu F; Liu Q; Lu R; Li W
Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
Fan S; He L; Sang D
Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
[TBL] [Abstract][Full Text] [Related]
13. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
Hu Y; Zhu Y; Wei X; Tang C; Zhang W
Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
[TBL] [Abstract][Full Text] [Related]
14. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.
Huang H; Zhang Y; Chen Z; Zeng X; Hu Z; Yang C
Heliyon; 2023 Apr; 9(4):e15157. PubMed ID: 37123934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.
Chen ZL; Zhao A; Li P; Zhang M; Yang J; Zhang L; Zhao X; Yang J; Wang L
Oncol Lett; 2018 Oct; 16(4):4614-4620. PubMed ID: 30214596
[TBL] [Abstract][Full Text] [Related]
18. Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil.
Xu Z; Hu C; Chen S; Zhang C; Yu J; Wang X; Lv H; Cheng X
Cancer Manag Res; 2019; 11():4905-4915. PubMed ID: 31213909
[No Abstract] [Full Text] [Related]
19. Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report.
Ding X; Ding J
Mol Clin Oncol; 2021 Aug; 15(2):151. PubMed ID: 34141430
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
